Ovarian cancer metastatic

9 trials 4 recruiting MedDRA PT
9 Registered trials
4 Recruiting
9 Unique sponsors
14 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
L Oncology (ATC L) 4
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
PARP inhibitor 3 substances
Antimetabolite 2 substances
Platinum compound 1 substance
Anthracycline 1 substance
Taxane 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Statin 1 substance
Phase III: 1 Phase II: 3 Phase I: 2 Phase I (Other): 2 Phase I (First in Human): 2

Filter these 9 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 9 trials

Phase III

1 trial
  • Pirkanmaan hyvinvointialue Academic
    ATORVASTATIN
    2024-515109-24-00 1 country 2023 n=240
    Recruiting

Phase II

3 trials
  • AGO Research GmbH Commercial
    CARBOPLATIN; DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL; GEMCITABINE HYDROCHLORIDE; NIRAPARIB TOSILATE MONOHYDRATE; OLAPARIB; PACLITAXEL; RUCAPARIB
    2024-516959-40-00 1 country 2021 n=136
    Ended
  • Esperas Pharma Inc. Commercial
    GEMCITABINE; GEMCITABINE HYDROCHLORIDE; N-[5-(2-METHOXY-6-METHYLPYRIDIN-3-YL)-1H-PYRAZOL-3-YL]-6-[(3R)-PIPERIDIN-3-YL]OXYPYRAZIN-2-AMINE
    2023-503459-91-00 2 countries 2023 n=12
    Ended
  • Esperas Pharma Inc. Academic
    GEMCITABINE; GEMCITABINE HYDROCHLORIDE; N-[5-(2-METHOXY-6-METHYLPYRIDIN-3-YL)-1H-PYRAZOL-3-YL]-6-[(3R)-PIPERIDIN-3-YL]OXYPYRAZIN-2-AMINE
    2023-503459-91-00 2 countries 2023 n=12
    Ended

Phase I

2 trials
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IMP not specified
    2025-524334-26-01 1 country 2026 n=15
    Recruiting
  • Genentech Inc. Commercial
    IMP not specified
    2023-509266-38-00 2 countries n=23
    Pending

Phase I (Other)

2 trials
  • Hospices Civils De Lyon Academic
    IMP not specified
    2024-515996-37-00 1 country 2021 n=15
    Halted
  • Karolinska University Hospital Academic
    IMP not specified
    2022-502918-87-00 1 country 2023 n=70
    Recruiting

Phase I (First in Human)

2 trials
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
  • Imcheck Therapeutics Commercial
    ALDESLEUKIN; ICT01; PEMBROLIZUMAB
    2024-514758-65-00 2 countries 2022 n=59
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Esperas Pharma Inc. Commercial 2 Phase II 0
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase I 1
Genentech Inc. Commercial 1 Phase I 0
AGO Research GmbH Commercial 1 Phase II 0
Daiichi Sankyo Inc. Commercial 1 Phase I (First in Human) 1
Imcheck Therapeutics Commercial 1 Phase I (First in Human) 0
Hospices Civils De Lyon Academic 1 Phase I (Other) 0
Karolinska University Hospital Academic 1 Phase I (Other) 1
Pirkanmaan hyvinvointialue Academic 1 Phase III 1
New trials by year
2021
2
2022
1
2023
4
2025
1
2026
1
← All indication landscapes